EPCAM and prostate cancer: Consistently, hybrid EMT of prostate cancer cells within a tumor organoid (tumoroid) was identified by the co-expression of epithelial (E-cadherin+ EpCAM+) and mesenchymal (Vimentin+) markers with enhanced stemness [13].